AtriCure Inc (ATRC) News

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

AtriCure to Participate in the Stifel 2024 Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

AtriCure Reports Third Quarter 2024 Financial Results

Worldwide revenue of $115.9 million – an increase of 17.9% year over year U.S. revenue of $95.5 million – an increase of 16.8% year over year...

AtriCure to Participate in the UBS Global Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage...

AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage...

AtriCure to Announce Third Quarter 2024 Financial Results

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage...

AtriCure a obtenu la certification de marquage CE pour la pince EnCompass®

Une approbation qui sert de nouveau vecteur de croissance à l'international pour AtriCure AtriCure, Inc. ( Nasdaq: ATRC ), leader en matière...

AtriCure erhält CE-Kennzeichnung für die EnCompass®-Klemme

Die Zulassung ist ein neuer Katalysator für das internationale Wachstum von AtriCure AtriCure, Inc. (Nasdaq: ATRC), ein führender Innovator im...

AtriCure Receives CE-Mark for the EnCompass® Clamp

Approval provides new catalyst for AtriCure’s international growth AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and...

Form 4 - Statement of changes in beneficial ownership of securities

AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage...

AtriCure bénéficie d'une indication élargie du marquage CE pour les dispositifs AtriClip ® qui permettent de réduire les accidents vasculaires cérébraux chez les patients souffrant de fibrillation auriculaire

Une indication élargie avec abondance de preuves cliniques à l'appui pour les dispositifs AtriClip AtriCure, Inc. ( Nasdaq : ATRC ), l'un des...

AtriCure erhält eine erweiterte CE-Kennzeichnung für AtriClip®-Geräte zur Reduzierung von Schlaganfällen bei Patienten mit Vorhofflimmern

Erweiterte Indikation auf Basis von zahlreichen klinischen Nachweisen für AtriClip-Geräte AtriCure, Inc. (Nasdaq: ATRC), ein führender Innovator...